UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 203

Sortiert nach

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Journal of clinical oncology, 2020-02, Vol.38 (5), p.395-405

2020

Volltextzugriff (PDF)

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions

Current medicinal chemistry, 2017-01, Vol.24 (15), p.1586

2017

Volltextzugriff (PDF)

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Clinical cancer research, 2013-07, Vol.19 (13), p.3621-3630

2013

Volltextzugriff (PDF)

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer

Nature communications, 2020-08, Vol.11 (1), p.4279-4279, Article 4279

2020

Volltextzugriff (PDF)

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

Clinical cancer research, 2017-10, Vol.23 (19), p.5757-5768

2017

Volltextzugriff (PDF)

Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

BMC urology, 2022-03, Vol.22 (1), p.33-14, Article 33

2022

Volltextzugriff (PDF)

Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer

Proceedings of the National Academy of Sciences - PNAS, 2015-02, Vol.112 (8), p.2515-2520

2015

Volltextzugriff (PDF)

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2108-2121

2004

Volltextzugriff (PDF)

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention

PloS one, 2011-12, Vol.6 (12), p.e28840

2011

Volltextzugriff (PDF)

Fingerprinting the circulating repertoire of antibodies from cancer patients

Nature biotechnology, 2003-01, Vol.21 (1), p.57-63

2003

Volltextzugriff (PDF)

345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A370-A370

2020

Volltextzugriff (PDF)

Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort

Oncoimmunology, 2019-01, Vol.8 (1), p.e1483303-e1483303

2019

Volltextzugriff (PDF)

Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products

Cancer research (Chicago, Ill.), 2005-07, Vol.65 (14), p.6189-6198

2005

Volltextzugriff (PDF)

Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7904-7910

2005

Volltextzugriff (PDF)

MP64-08 THE EFFECT OF COFFEE INTAKE AND RS762551 GENOTYPE ON SURVIVAL FOLLOWING PROSTATE CANCER DIAGNOSIS

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Volltextzugriff (PDF)

PD20-10 UPGRADING AT PROSTATECTOMY FOLLOWING INITIATION OF ACTIVE SURVEILLANCE IN MEN WITH LOCALIZED PROSTATE CANCER

The Journal of urology, 2018-04, Vol.199 (4), p.e405-e405

2018

Volltextzugriff (PDF)

KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer

Future oncology (London, England), 2021-08, Vol.17 (23), p.3017-3026

2021

Volltextzugriff (PDF)

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Nature genetics, 2021-01, Vol.53 (1), p.65-75

2021

Volltextzugriff (PDF)

Association analyses identify 31 new risk loci for colorectal cancer susceptibility

Nature communications, 2019-05, Vol.10 (1), p.2154-15, Article 2154

2019

Volltextzugriff (PDF)

Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction

Bioinformatics, 2019-10, Vol.35 (19), p.3709-3717

2019

Volltextzugriff (PDF)

Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer

Clinical cancer research, 2008-06, Vol.14 (12), p.3729-3736

2008

Volltextzugriff (PDF)

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan

Advances in therapy, 2022-05, Vol.39 (5), p.2236-2255

2022

Volltextzugriff (PDF)

Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients

Carcinogenesis (New York), 2017-08, Vol.38 (8), p.821-826

2017

Volltextzugriff (PDF)

Inverse Relationship between 15-Lipoxygenase-2 and PPAR-γ Gene Expression in Normal Epithelia Compared with Tumor Epithelia

Neoplasia (New York, N.Y.), 2005-03, Vol.7 (3), p.280-293

2005

Volltextzugriff (PDF)

1 – 25 von 203

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(195)
Mit Volltextzugriff
(171)

Publikationsform

Sprache

Englisch
(203)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention

Fingerprinting the circulating repertoire of antibodies from cancer patients

345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)

Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort

Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products

Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy

MP64-08 THE EFFECT OF COFFEE INTAKE AND RS762551 GENOTYPE ON SURVIVAL FOLLOWING PROSTATE CANCER DIAGNOSIS

PD20-10 UPGRADING AT PROSTATECTOMY FOLLOWING INITIATION OF ACTIVE SURVEILLANCE IN MEN WITH LOCALIZED PROSTATE CANCER

KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer

Association analyses identify 31 new risk loci for colorectal cancer susceptibility

Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction

Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan

Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients

Inverse Relationship between 15-Lipoxygenase-2 and PPAR-γ Gene Expression in Normal Epithelia Compared with Tumor Epithelia

Suchergebnisse filtern